Mississippi Cannabis: $6.43/g Flower, ~16% Capture, and 66,041 Patients Carrying a $138.9M Market

Mississippi's medical cannabis program generated $138.9M in CY 2025 across 66,041 active patient cardholders, capturing an estimated 16% of modeled demand at $6.43/g flower pricing. The third-year program is growing strongly — sales up 43.8% year-over-year, with patient enrollment up 33% — while dispensary count fell 14.5% (200 → 171) as the operator base finds equilibrium with patient demand. The estimated 16% capture reflects a structural ceiling characteristic of a registration-required medical framework: 66,041 cardholders against a modeled 378K Mississippi cannabis consumers means roughly one in six has any legal purchase pathway. The constraint is the card requirement; the program is doing what a medical-only framework can do.

Market Overview

Mississippi voters approved medical cannabis in November 2020 — 68.5% backed "either measure" over neither, and 73.7% chose Initiative 65 over the legislature's Alternative 65A — but the Mississippi Supreme Court invalidated the initiative in May 2021 over the state constitution's signature-distribution requirement. The legislature then enacted the Mississippi Medical Cannabis Act (Senate Bill 2095), signed February 2, 2022, with first legal sales on January 25, 2023 — making CY 2025 the program's third calendar year of sales. The program is administered jointly by the Mississippi State Department of Health Office of Medical Cannabis and the Mississippi Department of Revenue Alcohol Beverage Control Division. The program includes inhalable flower and pre-roll products, vaporization products, and separately-defined infused products.

Key metrics:

• 66,041 active patient cardholders (CY 2025, per MMCP Annual Report)
• $138.86M annual revenue (CY 2025); +43.8% YoY (2024: $96.55M, official)
• 171 active dispensaries (down from 200 in CY 2024)
• 110 cultivation entities (53 standard + 57 micro-cultivation licenses)
• 259 active certifying practitioners
• 66% flower-dominant product mix by units sold (Bud/Flower/Shake/Trim, per MMCP CY 2025 report); infused edibles 13%, concentrates 12%
• $6.43/g flower ($22.50 per 3.5g eighth, MMCP reported)
• ~10% combined effective tax burden (5% wholesale + 7% retail sales tax)
• Adults 21+: ~2.1 million
• ~16% estimated legal capture against TAM at Mississippi pricing

Flower Pricing

Mississippi flower at $6.43/g sits well below the medical-only norm and within the upper range of mature adult-use markets. The pricing is derived directly from MMCP's CY 2025 annual report ($22.50 average per 3.5g unit), not menu-scraped estimates. The structural read is that Mississippi's cultivation licensing has been competitive enough — 110 total cultivation entities, including 57 micro-cultivators — to produce real downward pressure on retail pricing.

Mississippi at $6.43/g (pre-tax) is competitive with mature adult-use markets like Maine and well below Pennsylvania, Arkansas, and other medical-only programs. Among medical-only markets, only West Virginia ($6.49/g) prices comparably. Mississippi's tax structure — a 5% upstream excise on first transfer plus the 7% retail sales tax — does not translate to a single clean consumer-facing rate, since the excise is embedded in wholesale cost rather than itemized at retail.

Tax Structure

• 5% excise tax on the first sale or transfer from cultivators/processors (per SB 2095)
• 7% state sales tax on retail cannabis sales
• License fees: $40,000 first year ($15,000 non-refundable application + $25,000 annual license), $25,000 annual renewal thereafter

The excise sits upstream on first transfer and is embedded in wholesale cost; the 7% sales tax applies at retail. The two do not combine into a single consumer-facing rate without margin and pass-through assumptions, but both rates are low relative to mature adult-use markets. Tax policy is not the binding constraint on Mississippi market scale.

Total Addressable Market

The framework's total addressable market estimate is a modeling scenario, not an official Mississippi measure. Applying the consumption baseline of 18% adult participation at 1.0 gram per day to Mississippi's roughly 2.1 million adults 21+:

• 2,100,000 adults 21+ (Census estimate)
• 378,000 modeled regular consumers (18% participation)
• 138 million grams modeled annual demand
• TAM at $6.43/g: ~$887M annually

Against $138.86M in CY 2025 actual sales, the implied legal market capture is ~16% under this scenario. The 66,041 active cardholders represent roughly 17.5% of the 378K modeled consumer base — about one in six has any legal purchase pathway, with the remainder sourcing through informal channels. Average monthly spend among active cardholders is approximately $175, broadly consistent with the 1.0 g/day reference at Mississippi's pricing. Because the participation and consumption assumptions are framework inputs rather than official program data, the 16% figure should be read as a modeled estimate rather than an observed market measure.

Revenue Trend

Mississippi's growth curve remains in expansion phase (the $96.55M 2024 total is the sum of the official 2024 annual report's four quarterly figures; the $138.86M CY 2025 figure is from the MMCP CY 2025 report; the 2023 total is estimated from the partial-year program ramp). The four CY 2025 quarters ran in a tight band between roughly $29.7M and $38.2M, with sequential growth decelerating across the year — a pattern consistent with the program approaching the natural ceiling of what a medical-only framework can capture from the state's modeled 378K consumer base.

Dispensary Density

Mississippi operates 171 medical cannabis dispensaries — down from 200 in CY 2024, a 14.5% decline. Net density: approximately 8.1 dispensaries per 100,000 adults 21+, placing Mississippi among the more retail-developed medical-only programs in the dataset.

Mississippi's 8.1 per 100K is the highest density in the medical-only set behind Pennsylvania's expanding network. The 200 → 171 reduction is structurally interesting — most medical-only markets are still in license-issuance growth mode, not consolidation. Average revenue per dispensary rose to approximately $812K in 2025 (from roughly $483K at the 2024 baseline of 200 stores against $96.55M in sales — a level below the threshold of sustainable operation for many operators given Mississippi's $25K annual license fee plus operating costs). The store base contracted while volume per surviving store roughly doubled, consistent with weaker operators exiting as the market consolidates.

Home Cultivation

Home cultivation is prohibited under Mississippi law. The program permits cultivation only by the 110 licensed cultivators, with no patient-grow exception — though home cultivation economics suggest legal home grow does little to undercut commercial pricing even where permitted. Mississippi borders no adult-use states (Tennessee, Alabama, Louisiana, and Arkansas all operate medical-only or restrictive programs), reducing the legal cross-border adult-use competition that affects programs like Pennsylvania and Utah, even if informal cross-border supply persists.

The Bottom Line

Mississippi's medical cannabis program is functioning well within its structural envelope. Sales grew 43.8% year-over-year, patient enrollment is up 33%, and flower pricing at $6.43/g is competitive with the most efficient medical-only programs in the dataset. The 14.5% dispensary contraction is natural market maturation — the early license-issuance excess working itself out as marginal operators exit and remaining stores consolidate volume at sustainable revenue levels. The modeled 16% capture reflects the structural ceiling characteristic of a registration-required medical framework: 66,041 cardholders against a modeled 378K consumer base means roughly one in six Mississippi cannabis consumers has any legal purchase pathway.

Federal rescheduling is no longer hypothetical. The MMCP CY 2025 report referenced the December 18, 2025 Trump executive order; since then, the DOJ issued an April 2026 final order moving FDA-approved cannabis products and state-licensed medical cannabis from Schedule I to Schedule III, effective immediately, with a broader rescheduling hearing beginning June 29, 2026 and proceedings extending into July. The change matters specifically for medical-only states like Mississippi: rescheduling to Schedule III removes the Section 280E deduction bar for state-licensed medical operators — a tax benefit that does not extend to adult-use cannabis, which remains Schedule I. Mississippi's medical-only operators therefore gain 280E relief that operators in adult-use states do not, alongside new compliance obligations the order introduces. Adult-use transition appears unlikely on any near-term horizon given the state's political environment. Mississippi looks structurally durable as a medical-only program of meaningful scale, with healthy growth fundamentals and competitive pricing holding within the access ceiling that defines it.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.